Travere Therapeutics, Inc. TVTX Business Segments — Income Tax Expense (Benefit)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s business segments — income tax expense (benefit).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s business segments — income tax expense (benefit)?
- Travere Therapeutics, Inc. (TVTX) reported business segments — income tax expense (benefit) of -$120K in Q1 2026.
- How has Travere Therapeutics, Inc.'s business segments — income tax expense (benefit) changed year-over-year?
- Travere Therapeutics, Inc.'s business segments — income tax expense (benefit) decreased by 407.7% year-over-year, from $39K to -$120K.
- What is the long-term trend for Travere Therapeutics, Inc.'s business segments — income tax expense (benefit)?
- Over 2 years (2022 to 2025), Travere Therapeutics, Inc.'s business segments — income tax expense (benefit) has grown at a 77.7% compound annual growth rate (CAGR), from $313K to $988K.
- What does business segments — income tax expense (benefit) mean?
- This metric represents the tax obligations or credits recognized by the company based on its taxable income or losses within the reporting period. It reflects the impact of the company's tax strategy and jurisdictional tax environment on its bottom line.